<DOC>
	<DOC>NCT02738905</DOC>
	<brief_summary>The purpose of this study is to determine if rifaximin reduces serum trimethylamine-N-oxide (TMAO) levels in patients with end-stage renal disease.</brief_summary>
	<brief_title>Impact of Rifaximin Therapy on Intestinal Byproducts in End-Stage Renal Disease</brief_title>
	<detailed_description>Study participants will undergo 3 study visits: baseline, day 7 (immediately post-therapy), day 21 (2 weeks post-therapy). All participants will provide blood and stool samples at each visit.</detailed_description>
	<mesh_term>Kidney Diseases</mesh_term>
	<mesh_term>Kidney Failure, Chronic</mesh_term>
	<mesh_term>Renal Insufficiency, Chronic</mesh_term>
	<mesh_term>Rifaximin</mesh_term>
	<mesh_term>Rifamycins</mesh_term>
	<criteria>Diagnosis of endstage renal disease Receiving chronic intermittent hemodialysis Patients with less advanced kidney disease Inability or unwillingness to provide informed consent Patients who may be pregnant Hemodynamically unstable patients Patients with liver failure, pancreatic insufficiency, or inflammatory bowel disease Patients with ongoing or recent infection and those with history of Cdiff infection Patients with abnormal bowel structure secondary to surgical or anatomic variations Patients on certain medications, including immunosuppressants, antidiarrheal agents, or recent (within the last 2 months) use of antibiotics</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>December 2016</verification_date>
</DOC>